Alemtuzumab as a Therapy for Chronic Lung Allograft Dysfunction in Lung Transplant Recipients With Short Telomeres

Alemtuzumab, a monoclonal antibody targeting CD52 that causes lymphocyte apoptosis, is a form of advanced immunosuppression that is currently used as a therapy for refractory acute cellular rejection and chronic lung allograft dysfunction in lung transplant recipients (1–3). Side effects of alemtuzu...

Descripción completa

Detalles Bibliográficos
Autores principales: Trindade, Anil J., Thaniyavarn, Tany, Townsend, Keri, Klasek, Robin, Tsveybel, Karen P., Kennedy, John C., Goldberg, Hilary J., El-Chemaly, Souheil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270280/
https://www.ncbi.nlm.nih.gov/pubmed/32547557
http://dx.doi.org/10.3389/fimmu.2020.01063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270280/
https://www.ncbi.nlm.nih.gov/pubmed/32547557
http://dx.doi.org/10.3389/fimmu.2020.01063

Ejemplares similares